VFY — Vitrafy Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00- AU$92.58m
- AU$115.92m
- AU$0.04m
Annual balance sheet for Vitrafy Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 7.38 | 0.963 | 1.72 | 6.41 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0.747 | 1.97 | 2.18 | 2.24 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 8.3 | 3.49 | 3.9 | 9.03 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.207 | 0.879 | 1.03 | 0.746 |
| Total Assets | 8.51 | 4.37 | 4.93 | 9.78 |
| Accounts Payable | ||||
| Payable / Accrued | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.544 | 11.3 | 19 | 33.9 |
| Long Term Debt | ||||
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 8.23 | 11.6 | 19.6 | 34.4 |
| Common Stock | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 0.285 | -7.27 | -14.6 | -24.6 |
| Total Liabilities & Shareholders' Equity | 8.51 | 4.37 | 4.93 | 9.78 |
| Total Common Shares Outstanding |